Tags

Type your tag names separated by a space and hit enter

The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
J Infect Dis 1993; 167(2):494-7JI

Abstract

The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine. Mice infected with lethal inocula of tachyzoites or cysts of Toxoplasma gondii and treated with doses of atovaquone, pyrimethamine, or sulfadiazine that were ineffective when administered alone had 70% survival when pyrimethamine plus atovaquone and 100% survival when sulfadiazine plus atovaquone was used. Of interest, doses of pyrimethamine and, particularly, sulfadiazine far below the doses that would induce any protection in infected mice were active when combined with atovaquone. These results suggest that clinical trials for treatment of toxoplasmosis in AIDS patients using the combination of atovaquone with sulfadiazine or pyrimethamine are justified.

Authors+Show Affiliations

Research Institute, Palo Alto Medical Foundation, CA 94301.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8421189

Citation

Araujo, F G., et al. "The Activity of Atovaquone (566C80) in Murine Toxoplasmosis Is Markedly Augmented when Used in Combination With Pyrimethamine or Sulfadiazine." The Journal of Infectious Diseases, vol. 167, no. 2, 1993, pp. 494-7.
Araujo FG, Lin T, Remington JS. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J Infect Dis. 1993;167(2):494-7.
Araujo, F. G., Lin, T., & Remington, J. S. (1993). The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. The Journal of Infectious Diseases, 167(2), pp. 494-7.
Araujo FG, Lin T, Remington JS. The Activity of Atovaquone (566C80) in Murine Toxoplasmosis Is Markedly Augmented when Used in Combination With Pyrimethamine or Sulfadiazine. J Infect Dis. 1993;167(2):494-7. PubMed PMID: 8421189.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. AU - Araujo,F G, AU - Lin,T, AU - Remington,J S, PY - 1993/2/1/pubmed PY - 1993/2/1/medline PY - 1993/2/1/entrez SP - 494 EP - 7 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 167 IS - 2 N2 - The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine. Mice infected with lethal inocula of tachyzoites or cysts of Toxoplasma gondii and treated with doses of atovaquone, pyrimethamine, or sulfadiazine that were ineffective when administered alone had 70% survival when pyrimethamine plus atovaquone and 100% survival when sulfadiazine plus atovaquone was used. Of interest, doses of pyrimethamine and, particularly, sulfadiazine far below the doses that would induce any protection in infected mice were active when combined with atovaquone. These results suggest that clinical trials for treatment of toxoplasmosis in AIDS patients using the combination of atovaquone with sulfadiazine or pyrimethamine are justified. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/8421189/The_activity_of_atovaquone__566C80__in_murine_toxoplasmosis_is_markedly_augmented_when_used_in_combination_with_pyrimethamine_or_sulfadiazine_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/167.2.494 DB - PRIME DP - Unbound Medicine ER -